» Articles » PMID: 15786716

Reduced Inhibitor 1 and 2 Activity is Associated with Increased Protein Phosphatase Type 1 Activity in Left Ventricular Myocardium of One-kidney, One-clip Hypertensive Rats

Overview
Publisher Springer
Specialty Biochemistry
Date 2005 Mar 25
PMID 15786716
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: In failing hearts, although protein phosphatase type 1 (PP1) activity has increased, information about the regulation and status of PP1 inhibitor-1 (INH-1) and inhibitor-2 (INH-2) is limited. In this study, we examined activity and protein expression of PP1, INH-1 and INH-2 and phosphorylation of sarcoplasmic reticulum (SR) phospholamban (PLB), a substrate of PP1 and modulator of SR Ca2+-ATPase activity, in failing and non-failing hearts. These studies were performed in LV myocardium of seven rats with chronic renal hypertension produced by Goldblatt's one-kidney, one-clip procedure and seven age-matched sham-operated normal controls (CTR). Eight weeks after surgery, LV ejection fraction, LV hypertrophy, and pulmonary congestion were determined in all rats. PP1 activity (nmol 32P/min/mg non-collagen protein) was assessed in LV homogenates using 32P-labeled phosphorylase a as substrate. INH-1 and INH-2 activity was determined in the immunoprecipitate of LV homogenates and expressed as percentage inhibitory activity. Using a specific antibody, LV tissue levels of PP1C and calsequestrin (CSQ), a SR calcium binding protein, which is not altered in failing hearts, were also determined. Further, total and phosphorylated PLB, INH-1 and INH-2 protein levels were determined in the LV homogenate and phosphoprotein-enriched fraction, respectively. The band density of each protein was quantified in densitometric units and normalized to CSQ.

Results: rats with chronic renal hypertension exhibited significantly reduced LV ejection fraction and increased LV hypertrophy and pulmonary congestion, characteristics of chronic heart failure (CHF). We found that compared to CTR, (1) both INH-1 (10.2+/-2 versus 57.5+/-1; p < 0.05) and INH-2 activity (3.8+/-0.4 versus 36.2+/-4; p < 0.05) were reduced, (2) total and phosphorylated PLB amount reduced, (3) protein level of phosphorylated INH-1 was reduced (2.32+/-0.1 versus 0.73+/-0.04; p < 0.05) whereas that of phosphorylated INH-2 increased (3.05+/-0.3 versus 1.42+/-0.1; p < 0.05), and (4) PP1 activity was increased approximately 2.6-fold in rats with CHF (1.59+/-0.05 versus 0.61+/-0.01; p < 0.05) while protein level of the catalytic subunit of PP1 (PP1C) increased 3.85-fold (0.77+/-0.05 versus 0.20+/-0.02; p < 0.05). These results suggest that reduced inhibitory INH-1 and INH-2 activity, increased PP1C protein level, and reduced PLB phosphorylation are associated with increased PP1 activity in failing hearts.

Citing Articles

Cardiac-Specific Suppression of Valosin-Containing Protein Induces Progressive Heart Failure and Premature Mortality Correlating with Temporal Dysregulations in mTOR Complex 2 and Protein Phosphatase 1.

Sun X, Tang X, Qiu H Int J Mol Sci. 2024; 25(12).

PMID: 38928151 PMC: 11203954. DOI: 10.3390/ijms25126445.


Abnormal phosphorylation / dephosphorylation and Ca dysfunction in heart failure.

Liu Y, Wang Q, Song Y, Song X, Fan Y, Kong L Heart Fail Rev. 2024; 29(4):751-768.

PMID: 38498262 DOI: 10.1007/s10741-024-10395-w.


Age-Dependent Protein Expression of Serine/Threonine Phosphatases and Their Inhibitors in the Human Cardiac Atrium.

Gergs U, Trapp T, Bushnaq H, Simm A, Silber R, Neumann J Adv Med. 2019; 2019:2675972.

PMID: 30719459 PMC: 6334353. DOI: 10.1155/2019/2675972.


Global comparison of phosphoproteins in human and rodent hearts: implications for translational studies of myosin light chain and troponin phosphorylations.

Kotlo K, Samarel A, Chen H, Aldstadt J, Danziger R Springerplus. 2016; 5(1):808.

PMID: 27390648 PMC: 4916117. DOI: 10.1186/s40064-016-2469-x.


Restoration of Mitochondrial Cardiolipin Attenuates Cardiac Damage in Swine Renovascular Hypertension.

Eirin A, Ebrahimi B, Kwon S, Fiala J, Williams B, Woollard J J Am Heart Assoc. 2016; 5(6).

PMID: 27247333 PMC: 4937260. DOI: 10.1161/JAHA.115.003118.


References
1.
Huang B, Wang S, Qin D, Boutjdir M, El-Sherif N . Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G(i) protein, phosphodiesterase, and phosphatases. Circ Res. 1999; 85(9):848-55. DOI: 10.1161/01.res.85.9.848. View

2.
Sabbah H, Sharov V, Gupta R, Mishra S, Rastogi S, Undrovinas A . Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ Res. 2003; 93(11):1095-101. DOI: 10.1161/01.RES.0000101932.70443.FE. View

3.
El-Armouche A, Rau T, Zolk O, Ditz D, Pamminger T, Zimmermann W . Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J. 2003; 17(3):437-9. DOI: 10.1096/fj.02-0057fje. View

4.
Kaiser R, Bueno O, Lips D, Doevendans P, Jones F, Kimball T . Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem. 2004; 279(15):15524-30. DOI: 10.1074/jbc.M313717200. View

5.
Mishra S, Gupta R, Tiwari N, Sharov V, Sabbah H . Molecular mechanisms of reduced sarcoplasmic reticulum Ca(2+) uptake in human failing left ventricular myocardium. J Heart Lung Transplant. 2002; 21(3):366-73. DOI: 10.1016/s1053-2498(01)00390-4. View